115 related articles for article (PubMed ID: 7576981)
1. Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro.
Fulda S; Honer M; Menke-Moellers I; Berthold F
Eur J Cancer; 1995; 31A(4):616-21. PubMed ID: 7576981
[TBL] [Abstract][Full Text] [Related]
2. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
Fulda S; Oster W; Berthold F
Anticancer Drugs; 1997 Jan; 8(1):34-41. PubMed ID: 9147609
[TBL] [Abstract][Full Text] [Related]
3. Use of human neuroblastoma continuous cell lines for in vitro drug sensitivity screening.
Hill BT; Whelan RD; Hosking LK
Invest New Drugs; 1988 Apr; 6(1):11-8. PubMed ID: 3410662
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Keshelava N; Seeger RC; Groshen S; Reynolds CP
Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
[TBL] [Abstract][Full Text] [Related]
5. Differential drug sensitivity of human neuroblastoma cells.
Spengler BA; Ross RA; Biedler JL
Cancer Treat Rep; 1986 Aug; 70(8):959-65. PubMed ID: 3731152
[TBL] [Abstract][Full Text] [Related]
6. The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
Wickström M; Johnsen JI; Ponthan F; Segerström L; Sveinbjörnsson B; Lindskog M; Lövborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
Mol Cancer Ther; 2007 Sep; 6(9):2409-17. PubMed ID: 17876040
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines.
Pelidis MA; Carducci MA; Simons JW
Int J Oncol; 1998 Apr; 12(4):889-93. PubMed ID: 9499451
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Fulda S; Fichtner I; Hero B; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):199-202. PubMed ID: 11464883
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
Johnsen JI; Pettersen I; Ponthan F; Sveinbjørnsson B; Flaegstad T; Kogner P
Int J Oncol; 2004 Dec; 25(6):1849-57. PubMed ID: 15547726
[TBL] [Abstract][Full Text] [Related]
10. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance in human neuroblastoma cell lines correlates with clinical therapy.
Keshelava N; Seeger RC; Reynolds CP
Eur J Cancer; 1997 Oct; 33(12):2002-6. PubMed ID: 9516842
[TBL] [Abstract][Full Text] [Related]
12. Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.
Bernhardt G; Reile H; Birnböck H; Spruss T; Schönenberger H
J Cancer Res Clin Oncol; 1992; 118(1):35-43. PubMed ID: 1309532
[TBL] [Abstract][Full Text] [Related]
13. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
Paffhausen T; Schwab M; Westermann F
Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
[TBL] [Abstract][Full Text] [Related]
14. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.
Fichtner I; Lemm M; Becker M; Berthold F
Anticancer Drugs; 1997 Feb; 8(2):174-81. PubMed ID: 9073313
[TBL] [Abstract][Full Text] [Related]
15. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo preclinical chemotherapy studies of human neuroblastoma.
Siegel MM; Chung HS; Rucker N; Siegel SE; Seeger RC; Isaacs H; Benedict WF
Cancer Treat Rep; 1980; 64(8-9):975-9. PubMed ID: 7448832
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A
Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines.
Cowie FJ; Pritchard-Jones K; Renshaw J; Pinkerton CR
Int J Oncol; 1998 May; 12(5):1143-9. PubMed ID: 9538141
[TBL] [Abstract][Full Text] [Related]
19. [In vitro chemosensitivity test for seven undifferentiated thyroid carcinoma cell lines using MTT assay].
Osawa Y; Yoshida A; Asaga T; Kawahara S; Yanoma S
Gan To Kagaku Ryoho; 1996 Mar; 23(4):471-6. PubMed ID: 8678500
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial effects of the guanidino group-containing cytostatic drugs, m-iodobenzylguanidine and methylglyoxal bis (guanylhydrazone).
Loesberg C; Van Rooji H; Romijn JC; Smets LA
Biochem Pharmacol; 1991 Jul; 42(4):793-8. PubMed ID: 1867636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
